🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Jimmy Ouellet PhD, Chief Scientist at Depixus will be presenting a poster entitled ‘Detection of genetic variation and base modifications at base-pair resolution on single molecules of native DNA’ at CLEPIC 2022, Szczecin, Poland, this week. We look forward to seeing you there!

Dr Christine Blancher, Head of Applications & Collaborations at Depixus is participating in the European Association for Cancer Research (EACR) Cancer Genomics event in Oxford, from 5 to 7 July.

Check out our hot new job opportunities on Welcome to the Jungle:welcometothejungle.com/fr/companies/d…

Gordon Hamilton, CEO of Depixus and Jimmy Ouellet, Chief Scientific Officer of Depixus will be participating in Discovery on Target, Boston, this week, 17 - 20 October. We look forward to seeing you there!

Dr Christine Blancher, Head of Applications & Collaborations, and Dr Nigel Skinner, Head of Product Management & Marketing, of Depixus®, will be participating in the Annual ASHG Meeting, from 25 – 29 October, in Los Angeles. We look forward to seeing you there!

Depixus is a 2022 Healthtech Finalist of European Lifestar Awards! Celebrating the advancement of #biotech #medtech #healthtech over the last 12 months Learn more about Depixus at depixus.com

Gordon Hamilton MD, CEO, Dr Steve Allen, Chief Business Officer and Dr Nigel Skinner, Head of Marketing & Product Management, at Depixus will be participating in the 5th RNA-targeted Drug Discovery Summit in Boston, this week, 13 - 15 December.

Dr Gordon Hamilton, CEO, and Dr Steve Allen, Chief Business Officer of Depixus, will be in San Francisco for the 41st Annual JP Morgan Healthcare Conference, which will be held from 9 to 12 January. lnkd.in/gkACrmv

Gordon Hamilton MD, CEO, and Dr Nigel Skinner, Head of Marketing & Product Management, will be at AGBT this coming week, presenting a poster entitled 'MAGNA™: single molecule real-time analysis of dynamic nucleic acid interactions’. We look forward to meeting you at AGBT!

Gordon Hamilton MD, CEO of Depixus, will be participating in the RNA Leaders Europe Congress in Basel, this coming week, 15 – 16 March. Depixus will be presenting a poster entitled 'MAGNA™: single molecule real-time analysis of dynamic nucleic acid interactions’.

Dr Christine Blancher, Head of Applications & Collaborations and Dr Zhen Wang, Principal Scientist at Depixus, will be presenting posters at the CHI Drug Discovery Conference section on ‘RNA-Targeting Small Molecule Drugs’, from 11 — 12 April, in San Diego.

Depixus is participating in the RNA Assay Development & Screening Summit in Boston this week! We will be talking about how we are addressing the biggest bottleneck in the screening of leads using its powerful new MAGNA™ technology. We look forward to meeting you there!

WEBINAR - Wednesday, 11 October at 4:30 p.m. CEST/ 10:30 a.m. EDT Gordon Hamilton, President & CEO, will talk about how MAGNA™, an exciting new technology from Depixus based on magnetic force spectroscopy, can be used to: us02web.zoom.us/webinar/regist…

Don’t miss CEO, Gordon Hamilton's presentation: “Magnetic force spectroscopy – a novel approach to Improve the hit-to-lead and lead optimization phases of RNA-targeted small-molecule drug discovery.” ⏰ 8:30am EDT 🗓 Day 2: Wednesday 27th September 📍 Boston, MA, USA

Counting down the days till #BSI2023! 🌟We’re looking forward to connecting with the structural biology community to exploreg the frontiers of biophysics. Meet up with Nigel Skinner & Adeline Feri from the Depixus team at BSI 2023 to discover how MAGNA™ can accelerate research!

Interactomics pioneer Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA™ technology to accelerate the Japanese healthcare leader’s RNA-targeted drug discovery program. businesswire.com/news/home/2023…™-Technology-to-Accelerate-RNA-targeted-Drug-Discovery

Depixus has launched its game-changing MAGNA technology access program with the deployment of the first ‘MAGNA One’ beta prototype instrument in the laboratory of Professor Jean-François Allemand, Department of Physics at ENS, Paris. Learn more at Depixus.com/press-release

Depixus has appointed experienced life sciences sales leader, Steve Klose, to the newly created role of Chief Commercial Officer. Klose will lead the company’s commercial growth strategy to build a highly effective sales organization. Learn more at Depixus.com/press-release